Annual Drug Patent Expirations for REXULTI
Rexulti is a drug marketed by Otsuka and is included in one NDA. It is available from two suppliers. There are six patents protecting this drug.
Drug patent litigation for REXULTI.
This drug has sixty-five patent family members in thirty-seven countries.
The generic ingredient in REXULTI is brexpiprazole. Two suppliers are listed for this compound. Additional details are available on the brexpiprazole profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
